{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:46:55Z","timestamp":1793713615410,"version":"4.6.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1097\/md.0000000000010620","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T16:43:36Z","timestamp":1525279416000},"page":"e0620","source":"Crossref","is-referenced-by-count":14,"title":["CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines"],"prefix":"10.1097","volume":"97","author":[{"given":"Ti-Kun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-38-20210309","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"R2-38-20210309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of myasthenia gravis based on its immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"R3-38-20210309","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0032-1329200","article-title":"Myasthenia gravis","volume":"32","author":"Silvestri","year":"2012","journal-title":"Semin Neurol"},{"key":"R4-38-20210309","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mus.21862","article-title":"Muscle strength and fatigue in patients with generalized myasthenia gravis","volume":"43","author":"Haran","year":"2011","journal-title":"Muscle Nerve"},{"key":"R6-38-20210309","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"R7-38-20210309","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol"},{"key":"R8-38-20210309","first-page":"574","article-title":"[Studies on the genetic pathogenesis of myasthenia gravis caused by CTLA-4 gene polymorphism]","volume":"21","author":"Mao","year":"2004","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"R9-38-20210309","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann Neurol"},{"key":"R10-38-20210309","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clim.2008.05.006","article-title":"Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis","volume":"128","author":"Gu","year":"2008","journal-title":"Clin Immunol"},{"key":"R11-38-20210309","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"Pillars article: CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"J Immunity"},{"key":"R12-38-20210309","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R13-38-20210309","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"R14-38-20210309","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1415938","article-title":"Genetic basis for clinical response to CTLA-4 blockade","volume":"372","author":"Snyder","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-38-20210309","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1517\/14656566.2011.629187","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma","volume":"12","author":"Wang","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R16-38-20210309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"Wang","year":"2008","journal-title":"J Intern Med"},{"key":"R17-38-20210309","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-38-20210309","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cca.2013.05.002","article-title":"Gene methylation in gastric cancer","volume":"424","author":"Qu","year":"2013","journal-title":"Clin Chim Acta"},{"key":"R19-38-20210309","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ajhg.2010.02.005","article-title":"Genetic control of individual differences in gene-specific methylation in human brain","volume":"86","author":"Zhang","year":"2010","journal-title":"Am J Hum Genet"},{"key":"R20-38-20210309","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","article-title":"Gene body methylation can alter gene expression and is a therapeutic target in cancer","volume":"26","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"R21-38-20210309","doi-asserted-by":"crossref","first-page":"e101986","DOI":"10.1371\/journal.pone.0101986","article-title":"CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"R23-38-20210309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/ecn.2015.0367","article-title":"Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients","volume":"26","author":"Chunjie","year":"2015","journal-title":"Eur Cytokine Netw"},{"key":"R24-38-20210309","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-38-20210309","doi-asserted-by":"crossref","first-page":"13341","DOI":"10.1074\/jbc.M413412200","article-title":"Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L","volume":"280","author":"Gowher","year":"2005","journal-title":"J Biol Chem"},{"key":"R26-38-20210309","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/art.38715","article-title":"Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway","volume":"66","author":"Cribbs","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R27-38-20210309","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/sj.gene.6363816","article-title":"CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis","volume":"3","author":"Wang","year":"2002","journal-title":"Genes Immun"},{"key":"R28-38-20210309","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-5728(00)00191-0","article-title":"Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis","volume":"105","author":"Huang","year":"2000","journal-title":"J Neuroimmunol"},{"key":"R29-38-20210309","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-5728(02)00228-X","article-title":"Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence","volume":"130","author":"Wang","year":"2002","journal-title":"J Neuroimmunol"},{"key":"R30-38-20210309","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3892\/ijmm.2013.1427","article-title":"Association between mRNA levels of DNMT1, DNMT3A, DNMT3B, MBD2 and LINE-1 methylation status in infants with tetralogy of Fallot","volume":"32","author":"Sheng","year":"2013","journal-title":"Int J Mol Med"},{"key":"R31-38-20210309","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ng.3258","article-title":"Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells","volume":"47","author":"Liao","year":"2015","journal-title":"Nat Genet"},{"key":"R32-38-20210309","doi-asserted-by":"crossref","first-page":"e1001106","DOI":"10.1371\/journal.pgen.1001106","article-title":"DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo","volume":"6","author":"Wienholz","year":"2010","journal-title":"PLoS Genet"},{"key":"R33-38-20210309","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1128\/MCB.01380-07","article-title":"Synergistic function of DNA methyltransferases Dnmt3a and Dnmt3b in the methylation of Oct4 and Nanog","volume":"27","author":"Li","year":"2007","journal-title":"Mol Cell Biol"},{"key":"R34-38-20210309","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.stem.2014.06.018","article-title":"Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells","volume":"15","author":"Challen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"R35-38-20210309","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R36-38-20210309","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R37-38-20210309","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"R38-38-20210309","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00415-006-0171-6","article-title":"Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin's disease","volume":"253","author":"Ferro","year":"2006","journal-title":"J Neurol"},{"key":"R39-38-20210309","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/jaut.2001.0541","article-title":"HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production","volume":"17","author":"Poussin","year":"2001","journal-title":"J Autoimmun"},{"key":"R40-38-20210309","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.07.003","article-title":"Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells","volume":"14","author":"Jiang","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"R41-38-20210309","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2008.12.005","article-title":"Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1\/Th2\/Th17\/Treg cell subsets through the secretion of TGF-beta","volume":"207","author":"Kong","year":"2009","journal-title":"J Neuroimmunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:06:49Z","timestamp":1620961609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201805040-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010620","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}